Three local drug makers—ACME Laboratories, Ibn Sina Pharmaceutical, and Healthcare Pharmaceuticals—are set to commence full-scale production of active pharmaceutical ingredients (APIs) at BSCIC API Industrial Park in Munshiganj, pending final regulatory approvals. Despite challenges like lacking gas connections and a functional effluent treatment plant, production has begun on a limited scale. Bangladesh, which already meets 97% of domestic pharmaceutical demand, still imports 85% of APIs, costing $1.3 billion annually. Local API production could cover 50% of demand, reducing reliance on imports and boosting the industry’s growth potential.
BIZDATAINSIGHTS
Bizdata Insights is a Market Insights, Data Intelligence and Business Advisory Platform
Our Solutions
Menu
Newsletter
Sign up for our newsletter now by entering your e-mail address and never miss out on the latest news and updates from our team!